Pharma merger and acquisition news... Jul 22
Gritstone Oncology advances into phase 2 expansion cohorts for its personalized neoantigen immunotherapy GRANITE and its off-the-shelf neoantigen immunotherapy SLATE ... Nov 03
European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer.... Nov 02
Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers... Oct 07
... Sep 23
-Advertisements-